Editas Medicine, Inc. (EDIT): Price and Financial Metrics

Editas Medicine, Inc. (EDIT): $13.04

-0.43 (-3.19%)

POWR Rating

Component Grades













Add EDIT to Watchlist
Sign Up

Industry: Biotech



in industry


  • EDIT scores best on the Growth dimension, with a Growth rank ahead of 85.55% of US stocks.
  • The strongest trend for EDIT is in Growth, which has been heading up over the past 179 days.
  • EDIT's current lowest rank is in the Stability metric (where it is better than 4.36% of US stocks).

EDIT Stock Summary

  • With a price/sales ratio of 54.83, Editas Medicine Inc has a higher such ratio than 96.38% of stocks in our set.
  • As for revenue growth, note that EDIT's revenue has grown -71.85% over the past 12 months; that beats the revenue growth of only 1.8% of US companies in our set.
  • In terms of volatility of its share price, EDIT is more volatile than 95.39% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Editas Medicine Inc are ACRS, AKTS, TBPH, CUE, and FREQ.
  • EDIT's SEC filings can be seen here. And to visit Editas Medicine Inc's official web site, go to www.editasmedicine.com.

EDIT Valuation Summary

  • EDIT's price/sales ratio is 53.5; this is 1307.89% higher than that of the median Healthcare stock.
  • EDIT's price/earnings ratio has moved down 17.1 over the prior 68 months.
  • EDIT's price/earnings ratio has moved down 17.1 over the prior 68 months.

Below are key valuation metrics over time for EDIT.

Stock Date P/S P/B P/E EV/EBIT
EDIT 2021-08-31 53.5 7.1 -26.0 -24.1
EDIT 2021-08-30 52.0 6.9 -25.3 -23.4
EDIT 2021-08-27 55.1 7.3 -26.8 -24.9
EDIT 2021-08-26 53.7 7.1 -26.2 -24.2
EDIT 2021-08-25 55.2 7.3 -26.9 -24.9
EDIT 2021-08-24 54.4 7.2 -26.5 -24.6

EDIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EDIT has a Quality Grade of D, ranking ahead of 12.21% of graded US stocks.
  • EDIT's asset turnover comes in at 0.12 -- ranking 248th of 682 Pharmaceutical Products stocks.
  • SMMT, SAGE, and VSTM are the stocks whose asset turnover ratios are most correlated with EDIT.

The table below shows EDIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.120 1 -0.458
2021-03-31 0.140 1 -0.450
2020-12-31 0.158 1 -0.468
2020-09-30 0.164 1 -0.447
2020-06-30 0.065 1 -0.704
2020-03-31 0.057 1 -0.806

EDIT Price Target

For more insight on analysts targets of EDIT, see our EDIT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.75 Average Broker Recommendation 1.79 (Moderate Buy)

EDIT Stock Price Chart Interactive Chart >

Price chart for EDIT

EDIT Price/Volume Stats

Current price $13.04 52-week high $73.03
Prev. close $13.47 52-week low $9.59
Day low $12.19 Volume 1,702,500
Day high $13.42 Avg. volume 1,821,511
50-day MA $12.42 Dividend yield N/A
200-day MA $25.07 Market Cap 895.08M

Editas Medicine, Inc. (EDIT) Company Bio

Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.

EDIT Latest News Stream

Event/Time News Detail
Loading, please wait...

EDIT Latest Social Stream

Loading social stream, please wait...

View Full EDIT Social Stream

Latest EDIT News From Around the Web

Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 21.79% and 181.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022 EDIT-301 remains on track to dose first sickle cell disease patient in 1H 2022 and first TDT patient in 2022 EDIT-103 for RHO-adRP and EDIT-202 for solid tumors advancing towards IND-enabling studies CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for t

Yahoo | February 24, 2022

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Yahoo | February 23, 2022

10 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming

In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […]

Yahoo | February 23, 2022

Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 4.05% and 324.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 17, 2022

Read More 'EDIT' Stories Here

EDIT Price Returns

1-mo 11.64%
3-mo -33.20%
6-mo -53.08%
1-year -70.36%
3-year -47.29%
5-year -23.83%
YTD -50.89%
2021 -62.13%
2020 136.78%
2019 30.15%
2018 -25.97%
2017 89.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4681 seconds.